Allogeneic hematopoietic cell transplantation for Hodgkin lymphoma: A concise review

Leukemia and Lymphoma

Volumn 49, Issue 10, 2008, Pages 1854-1859

  Laport, Ginna ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allogeneic transplantation; Hodgkin lymphoma

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; FLUDARABINE; MELPHALAN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONFERENCE PAPER; CYTOREDUCTIVE SURGERY; DONOR LYMPHOCYTE INFUSION; GRAFT VERSUS LYMPHOMA EFFECT; HODGKIN DISEASE; HUMAN; MYELOABLATIVE CONDITIONING; PRIORITY JOURNAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; TREATMENT FAILURE;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 55049121436     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802304974     Document Type: Conference Paper

References (20)

1. Schmitz, N., Haverkamp, H. Josting, A. et al. (2005) Long term followup in advanced Hodgkins disease: Updated results of the HD-R1 study comparing conventional chemotherapy to high-dose chemotherapy with autologous hematopoietic stem cell transplantation of the German Hodgkin Study Group (GHSG) and the Working Party of the European Group for Blood and Marrow Transplantation (EBMT). J Clin Oncol, 23562
2. Moskowitz, C. H., Kewalramani, T. Nimer, S. D. et al. (2004) Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol, 124, pp. 645-652.
3. Linch, D. C., Winfield, D. Goldstone, A. H. et al. (1993) Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet, 341, pp. 1051-1054.
4. Anderlini, P., Swanston, N. Rashid, A. et al. (2008) Evidence of a graft-versus-Hodgkin lymphoma effect in the setting of extensive bone marrow involvement. Biol Blood Marrow Transplant, 14, pp. 478-480.
5. Thomson, K. J., Peggs, K. S. Smith, P. et al. (2008) Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation. Bone Marrow Transplant, 41, pp. 765-770.
6. Armand, P., Kim, H. T. Ho, V. T. et al. (2008) Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: Importance of histology for outcome. Biol Blood Marrow Transplant, 14, pp. 418-425.
7. Alvarez, I., Sureda, A. Caballero, M. D. et al. (2006) Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed hodgkin lymphoma: Results of a spanish prospective cooperative protocol. Biol Blood Marrow Transplant, 12, pp. 172-183.
8. Peniket, A. J., Ruiz de Elvira, M C Taghipour, G. et al. (2003) An EBMT registry matched study of allogeneic stem cell transplants for lymphoma: allogeneic transplantation is associated with a lower relapse rate but a higher procedure-related mortality rate than autologous transplantation. Bone Marrow Transplant, 31, pp. 667-678.
9. Gajewski, J. L., Phillips, G. L. Sobocinski, K. A. et al. (1996) Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol, 14, pp. 572-578.
10. Anderson, J. E., Litzow, M. R. Appelbaum, F. R. et al. (1993) Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol, 11, pp. 2342-2350.
11. Akpek, G., Ambinder, R. F. Piantadosi, S. et al. (2001) Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol, 19, pp. 4314-4321.
12. Armitage, J. O., Goldstone, A. H. Carella, A. M. et al. (1999) Role of bone marrow transplantation in Hodgkins disesae. Hodgkins Disease, pp. 521-530. Philadelphia, PA: Lippincott-Williams and Wilkins
13. Sureda, A., Robinson, S. Canals, C. et al. (2008) Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: An analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol, 26, pp. 455-462.
14. Anderlini, P., Saliba, R. Acholonu, S. et al. (2008) Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: The updated M.D. Anderson Cancer Center experience. Haematologica, 93, pp. 257-264.
15. Peggs, K. S., Hunter, A. Chopra, R. et al. (2005) Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet, 365, pp. 1934-1941.
16. Burroughs, L., O'Donnell, P. Sandmaier, B. et al. (2007) Comparison of allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with HLA-matched related, unrelated and related haploidentical donors for relapsed or refractory Hodgkin lymphoma. Blood, 11058
17. Carella, A. M., Cavaliere, M. Lerma, E. et al. (2000) Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol, 18, pp. 3918-3924.
18. Gallamini, A., Hutchings, M. Avigdor, A. et al. (2008) Early interim PET scan in Hodgkin lymphoma: Where do we stand?. Leuk Lymphoma, 49, pp. 659-662.
19. Hutchings, M., Loft, A. Hansen, M. et al. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, pp. 52-59.
20. Jabbour, E., Hosing, C. Ayers, G. et al. (2007) Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer, 109, pp. 2481-2489.